Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Venetoclax Combinations in Previously Untreated CLL/SLL (Japan)
jRCT2021210055Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Nov 2021
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of venetoclax, obinutuzumab and ibrutinib in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (2 arms), sponsored by AbbVie Inc. Primary endpoint: Complete Remission (CR) with Incomplete Marrow Recovery (CRi) Rate (IRC, modified 2008 iwCLL). Started Nov 2021; status: completed.
02
Drugs
venetoclaxobinutuzumabibrutinib
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on jRCT2021210055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021210055.